Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment
Recruitment status was: Not yet recruiting
RATIONALE: Studying samples of bone marrow and blood from patients with cancer who failed treatment may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer resistance. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies biomarkers in samples from adult patients with acute myeloid leukemia who failed standard-of-care treatment.
Genetic: DNA methylation analysis
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: nucleic acid sequencing
Other: laboratory biomarker analysis
|Official Title:||The Genetics of "Non-Response" in Adult AML|
- Genetic signature predictive of progression and drug resistance in AML
- Identification of biological pathways in non-responder AML patients
|Study Start Date:||September 2011|
|Estimated Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
- Define a "non-response" signature that will help up-front identification of cases of intermediate-risk acute myeloid leukemia (AML) destined to fail existing standard-of-care therapy.
- Identify biological pathways in the "non-response" group that can provide targets for novel therapeutics.
OUTLINE: DNA and RNA extracted from cryopreserved bone marrow cells and/or blood cells are analyzed for mutations and gene expression signatures (genome-wide methylation, mRNA and miRNA expression, and single nucleotide polymorphism (SNP) analysis) by microarray assays.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01421862
|Principal Investigator:||Jerry Radich, MD||Fred Hutchinson Cancer Research Center|